Fig. 9From: FAM168A participates in the development of chronic myeloid leukemia via BCR-ABL1/AKT1/NFκB pathwayFAM168A participates in the development of CML. FAM168A may act as a linker protein to bind to BCR-ABL1 and AKT1, which mediates the transmission of AKT1/NFκB signalBack to article page